JP2017519739A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519739A5
JP2017519739A5 JP2016569787A JP2016569787A JP2017519739A5 JP 2017519739 A5 JP2017519739 A5 JP 2017519739A5 JP 2016569787 A JP2016569787 A JP 2016569787A JP 2016569787 A JP2016569787 A JP 2016569787A JP 2017519739 A5 JP2017519739 A5 JP 2017519739A5
Authority
JP
Japan
Prior art keywords
gln
lys
thr
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519739A (ja
JP6697807B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/033042 external-priority patent/WO2015184177A1/en
Publication of JP2017519739A publication Critical patent/JP2017519739A/ja
Publication of JP2017519739A5 publication Critical patent/JP2017519739A5/ja
Application granted granted Critical
Publication of JP6697807B2 publication Critical patent/JP6697807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569787A 2014-05-28 2015-05-28 インスリン抵抗性のための改善されたペプチド医薬品 Active JP6697807B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004156P 2014-05-28 2014-05-28
US62/004,156 2014-05-28
PCT/US2015/033042 WO2015184177A1 (en) 2014-05-28 2015-05-28 Improved peptide pharmaceuticals for insulin resistance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020075470A Division JP2020143066A (ja) 2014-05-28 2020-04-21 インスリン抵抗性のための改善されたペプチド医薬品

Publications (3)

Publication Number Publication Date
JP2017519739A JP2017519739A (ja) 2017-07-20
JP2017519739A5 true JP2017519739A5 (enExample) 2018-07-12
JP6697807B2 JP6697807B2 (ja) 2020-05-27

Family

ID=54699825

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016569787A Active JP6697807B2 (ja) 2014-05-28 2015-05-28 インスリン抵抗性のための改善されたペプチド医薬品
JP2020075470A Pending JP2020143066A (ja) 2014-05-28 2020-04-21 インスリン抵抗性のための改善されたペプチド医薬品
JP2022127266A Pending JP2022172128A (ja) 2014-05-28 2022-08-09 インスリン抵抗性のための改善されたペプチド医薬品
JP2024067692A Pending JP2024102119A (ja) 2014-05-28 2024-04-18 インスリン抵抗性のための改善されたペプチド医薬品

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020075470A Pending JP2020143066A (ja) 2014-05-28 2020-04-21 インスリン抵抗性のための改善されたペプチド医薬品
JP2022127266A Pending JP2022172128A (ja) 2014-05-28 2022-08-09 インスリン抵抗性のための改善されたペプチド医薬品
JP2024067692A Pending JP2024102119A (ja) 2014-05-28 2024-04-18 インスリン抵抗性のための改善されたペプチド医薬品

Country Status (18)

Country Link
US (5) US9856306B2 (enExample)
EP (2) EP4397374A3 (enExample)
JP (4) JP6697807B2 (enExample)
KR (3) KR20230084337A (enExample)
CN (5) CN109865142A (enExample)
AU (2) AU2015266854B2 (enExample)
BR (1) BR112016027595B1 (enExample)
CA (1) CA2949701C (enExample)
DK (1) DK3155017T3 (enExample)
ES (1) ES2985732T3 (enExample)
FI (1) FI3155017T3 (enExample)
HU (1) HUE066179T2 (enExample)
IL (3) IL285613B2 (enExample)
MX (2) MX384236B (enExample)
NZ (2) NZ757113A (enExample)
PL (1) PL3155017T4 (enExample)
PT (1) PT3155017T (enExample)
WO (1) WO2015184177A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6148228B2 (ja) * 2011-05-18 2017-06-14 ユーメデリス ファーマシューティカルズ，インク． 改善されたペプチド製剤
KR102255479B1 (ko) 2011-05-18 2021-05-24 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
EP4047023A1 (en) * 2012-11-20 2022-08-24 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
EP4397374A3 (en) 2014-05-28 2024-10-16 Mederis Diabetes, LLC Improved peptide pharmaceuticals for insulin resistance
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2019018350A1 (en) 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
ES3002666T3 (en) 2018-01-03 2025-03-07 Mederis Diabetes Llc Improved peptide pharmaceuticals for treatment of nash and other disorders
BR112022016470A2 (pt) * 2020-02-21 2022-11-22 Spitfire Pharma Llc Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamífero
JP2024500324A (ja) * 2020-12-07 2024-01-09 スピットファイア ファーマ エルエルシー Ｇｌｐ－１ｒおよびｇｃｇｒ均衡アゴニストを使用した血糖および／または体重を低下させるための治療レジメンおよび方法
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CN113461747B (zh) * 2021-07-12 2023-02-03 吉林化工学院 刺玫果中2个具有降血糖活性的化合物
CN121219311A (zh) * 2023-05-24 2025-12-26 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (ja) 1997-08-15 1999-03-02 Asahi Glass Co Ltd オピオイド様ペプチド
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (ru) 2000-09-20 2002-04-27 Калюжин Олег Витальевич Производные мурамовой кислоты
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
HK1080090B (zh) 2001-10-10 2012-12-14 诺和诺德公司 肽的重构和糖缀合的方法
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
ITRM20040607A1 (it) 2004-12-15 2005-03-15 Biogen S R L Analoghi della dermorfina ad attivita' analgesica.
US7776819B2 (en) 2005-03-03 2010-08-17 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
WO2006121860A2 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2007002465A2 (en) 2005-06-23 2007-01-04 Rapid Pharmaceuticals, Llc Stabilizing alkylglycoside compositions and methods thereof
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
AU2009260302B2 (en) * 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
HUE026255T2 (en) 2009-07-13 2016-06-28 Zealand Pharma As Acylated glucagon analogues
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
KR101453037B1 (ko) 2011-03-23 2014-10-21 주식회사 엘지화학 전극조립체 및 이의 제조방법
JP6148228B2 (ja) 2011-05-18 2017-06-14 ユーメデリス ファーマシューティカルズ，インク． 改善されたペプチド製剤
KR102255479B1 (ko) * 2011-05-18 2021-05-24 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
EP4047023A1 (en) * 2012-11-20 2022-08-24 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
AU2014255608B2 (en) * 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
EP4397374A3 (en) 2014-05-28 2024-10-16 Mederis Diabetes, LLC Improved peptide pharmaceuticals for insulin resistance
WO2016065090A1 (en) * 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
ES3002666T3 (en) * 2018-01-03 2025-03-07 Mederis Diabetes Llc Improved peptide pharmaceuticals for treatment of nash and other disorders

Similar Documents

Publication Publication Date Title
JP2017519739A5 (enExample)
FI3155017T3 (fi) Parannettuja peptidilääkkeitä insuliiniresistenssiin
WO2017009236A3 (en) New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists
JP2015120736A5 (enExample)
JP2015517489A5 (enExample)
JP2017532343A5 (enExample)
JP2015078220A5 (enExample)
JP2017504611A5 (enExample)
JP2019517542A5 (enExample)
JP2016510326A5 (enExample)
JP2015510916A5 (enExample)
JP2013541583A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法
JP2017501140A5 (enExample)
JP2013166781A5 (enExample)
JP2017512194A5 (enExample)
JP2015518007A5 (enExample)
JP2010500284A5 (enExample)
JP2015531749A5 (enExample)
WO2015121457A8 (en) Fgf-8 for use in treating diseases or disorders of energy homeostasis
JP2012523416A5 (enExample)
JP2014525749A5 (enExample)
JP2017529355A5 (enExample)
JP2017061488A5 (enExample)
JP2009505991A5 (enExample)